Agenus Beheer
Beheer criteriumcontroles 3/4
De CEO Agenus is Garo Armen, benoemd in Jan1994, heeft een ambtstermijn van 32.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.35M, bestaande uit 53% salaris en 47% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.99% van de aandelen van het bedrijf, ter waarde $ 1.40M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 3.3 jaar.
Belangrijke informatie
Garo Armen
Algemeen directeur
US$1.4m
Totale compensatie
| Percentage CEO-salaris | 52.97% |
| Dienstverband CEO | 32.3yrs |
| Eigendom CEO | 1.0% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 3.3yrs |
Recente managementupdates
Recent updates
AGEN: Phase 3 Colorectal Cancer Trial Will Drive Bullish Reassessment
Analysts now set a higher price target for Agenus, moving their fair value estimate from $12.33 to $15.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Phase 2 data from the C-800-23 study in advanced cutaneous melanoma showed a 22% confirmed objective response rate for botensilimab plus balstilimab, with median overall survival of 16.6 months and a 42% 2 year overall survival rate in the overall cohort, and no treatment related deaths reported (Key Developments).
AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside
Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside
Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside
Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
BOT/BAL Trials And Cost Reductions Will Shape Future Advances
Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.Agenus: Novel Drugs That Just Are Not Novel
Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking AlphaThere's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...Agenus: 2024 May Finally Be The Year For A Major Turnaround
Summary Agenus is a beaten-down immuno-oncology biotech stock that has not participated in the recent biotech rally despite a promising pipeline and multiple partnerships. The company's lead asset, botensilimab (+/- balstilimab), has shown promising results in various advanced solid tumors (colorectal, pancreatic, melanoma, NSCLC, sarcomas, ovarian). A BLA is planned in mid-2024 for accelerated approval in metastatic colorectal cancer with potential for subsequent label expansion to earlier lines. Potential new partnerships are also being evaluated. Cash runway is a concern but planned transactions (sale of 2 assets and monetization of milestones/royalties from partnered programs) in 1H 2024 are expected to considerably extend cash runway. Considering AGEN's track record I am confident about these transactions. Read the full article on Seeking AlphaImproved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Agenus Inc.'s ( NASDAQ:AGEN ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a strong buy right now...News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Agenus Inc. ( NASDAQ:AGEN ) shareholders will have a reason to smile today, with the analysts making substantial...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$64m |
| Dec 31 2025 | US$1m | US$715k | -US$101k |
| Sep 30 2025 | n/a | n/a | -US$35m |
| Jun 30 2025 | n/a | n/a | -US$166m |
| Mar 31 2025 | n/a | n/a | -US$191m |
| Dec 31 2024 | US$4m | US$715k | -US$227m |
| Sep 30 2024 | n/a | n/a | -US$228m |
| Jun 30 2024 | n/a | n/a | -US$224m |
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$6m | US$710k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$263m |
| Mar 31 2023 | n/a | n/a | -US$240m |
| Dec 31 2022 | US$6m | US$689k | -US$220m |
| Sep 30 2022 | n/a | n/a | -US$215m |
| Jun 30 2022 | n/a | n/a | US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$10m | US$655k | -US$24m |
| Sep 30 2021 | n/a | n/a | US$4m |
| Jun 30 2021 | n/a | n/a | -US$226m |
| Mar 31 2021 | n/a | n/a | -US$190m |
| Dec 31 2020 | US$6m | US$677k | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$174m |
| Jun 30 2020 | n/a | n/a | -US$168m |
| Mar 31 2020 | n/a | n/a | -US$171m |
| Dec 31 2019 | US$10m | US$634k | -US$108m |
Compensatie versus markt: De totale vergoeding ($USD 1.35M ) Garo } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 632.19K ).
Compensatie versus inkomsten: De vergoeding van Garo is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Garo Armen (72 yo)
Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994 and serves as its Interim Chief Financial Officer & Principal Financial Officer since January 8, 2026. H...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 32.3yrs | US$1.35m | 0.99% $ 1.4m | |
| Chief Medical Officer | 5.3yrs | US$902.82k | 0.14% $ 194.8k | |
| Director and President & CEO of MiNK Therapeutics | 4.3yrs | geen gegevens | 0.044% $ 62.4k | |
| Senior Director | less than a year | geen gegevens | 0.022% $ 31.1k | |
| Chief Information Officer | 4.3yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations & Corporate Development | 1.5yrs | geen gegevens | geen gegevens | |
| Chief Communications & Government Relations Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Chief People Officer | 4.3yrs | geen gegevens | geen gegevens | |
| Member of Advisory Board & Chief Strategic Advisor | 2.5yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Head of Medical Affairs | less than a year | geen gegevens | geen gegevens | |
| Scientist II | no data | geen gegevens | geen gegevens |
Ervaren management: Het managementteam van AGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 27.3yrs | US$1.35m | 0.99% $ 1.4m | |
| Director and President & CEO of MiNK Therapeutics | 1.9yrs | geen gegevens | 0.044% $ 62.4k | |
| Member of Advisory Board & Chief Strategic Advisor | 3.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 1.8yrs | US$175.04k | 0.094% $ 133.0k | |
| Member of Advisory Board | 3.3yrs | US$1.04m | geen gegevens | |
| Member of Advisory Board | 1.3yrs | US$204.37k | geen gegevens | |
| Independent Lead Director | 19.4yrs | US$199.45k | 0.0067% $ 9.4k | |
| Member of Advisory Board | 3.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 19.2yrs | US$375.32k | 0.011% $ 15.7k | |
| Independent Director | 5.6yrs | US$150.04k | 0.014% $ 20.2k |
Ervaren bestuur: De raad van bestuur van AGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/28 21:42 |
| Aandelenkoers aan het einde van de dag | 2026/05/28 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Agenus Inc. wordt gevolgd door 7 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |